Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK1 | Q8N5S9 | 3/20 | 0.38 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 4/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2797310 | 0.97 | CAMKK1 (0.39) | CAMKK1CAMKK2EGFRERBB2ALDH1A1 | |
| SCHEMBL2799360 | 0.89 | EGFR (0.39) | EGFRERBB2LTA4H | |
| SCHEMBL3523231 | 0.87 | SPHK2 (0.44) | EGFRERBB2HRH3 | |
| SCHEMBL4923369 | 0.86 | S1PR1 (0.34) | CAMKK1CAMKK2ERBB2ALDH1A1 | |
| SCHEMBL4924585 | 0.82 | ALDH1A1 (0.36) | CAMKK1CAMKK2ALDH1A1FFAR1 | |
| SCHEMBL2797321 | 0.79 | CPT1A (0.36) | CAMKK1CAMKK2ALDH1A1LTA4HFFAR1 | |
| SCHEMBL5564355 | 0.75 | LTA4H (0.43) | LTA4H | |
| SCHEMBL3520160 | 0.74 | EGFR (0.59) | EGFRERBB2 | |
| SCHEMBL6111518 | 0.74 | EGFR (0.59) | EGFRERBB2 | |
| SCHEMBL3521645 | 0.74 | EGFR (0.65) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194556-A1 | Quinazolines and Their Use as Aurora Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| EP-1888572-A1 | QUINAZOLINES AND THEIR USE AS AURORA KINASE INHIBITORS | AstraZeneca AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006129064-A1 | QUINAZOLINES AND THEIR USE AS AURORA KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194556-A1 | Quinazolines and Their Use as Aurora Kinase Inhibitors | AURKA, AURKC, AURKB | CAMKK1 726/4885CAMKK2 795/4885EGFR 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.